Physician profile
Steven Hays
NPI 1073591566
$5,476.77
in general payments reported to CMS, 2019-2025
37 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $427 · 2021: $335 · 2022: $763 · 2023: $926 · 2024: $1,080 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573 · Education: $1.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.16 |
| Education | $1.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,139.61 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $566.68 | 2019-2025 | Veltassa |
| Amgen INC. | $479.14 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $344.91 | 2019-2024 | Jynarque |
| Veloxis Pharmaceuticals, INC. | $340.66 | 2019-2025 | Envarsus |
| Alexion Pharmaceuticals, INC. | $286.28 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $230.87 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $212.64 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $193.72 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $180.79 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $145.86 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $130.92 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $122.07 | 2022-2025 | |
| Amicus Therapeutics, INC. | $107.60 | 2019-2023 | Galafold |
| Nxstage Medical, INC. | $95.89 | 2022-2024 | Nxstage Pureflow Solution, Nxstage System One |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.